Loading...
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
Gillessen, S. Bossi, A. Davis, I. D. de Bono, J. Fizazi, K. James, N. D. Mottet, N. Shore, N. Small, E. Smith, M.
Gillessen, S.
Bossi, A.
Davis, I. D.
de Bono, J.
Fizazi, K.
James, N. D.
Mottet, N.
Shore, N.
Small, E.
Smith, M.
Citations
Altmetric:
Abstract
Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions in daily clinical practise. The 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) addressed some questions in these areas to supplement guidelines that mostly are based on level 1 evidence.
Objective: To present the voting results of the APCCC 2022.
Design, setting, and participants: The experts voted on controversial questions where high-level evidence is mostly lacking: locally advanced prostate cancer; biochemical recurrence after local treatment; metastatic hormone-sensitive, non-metastatic, and metaation-resistant prostate cancer (mCRPC), and oligometastatic and oligoprogressive prostate cancer.
Conclusions: These voting results in four specific areas from a panel of experts in advanced prostate cancer can help clinicians and patients navigate controversial areas of management for which high-level evidence is scant or conflicting and can help research funders and policy makers identify information gaps and consider what areas to explore further. However, diagnostic and treatment decisions always have to be individualised based on patient characteristics, including the extent and location of disease, prior treatment(s), co-morbidities, patient preferences, and treatment recommendations and should also incorporate current and emerging clinical evidence and logistic and economic factors. Enrolment in clinical trials is strongly encouraged. Importantly, APCCC 2022 once again identified important gaps where there is non-consensus and that merit evaluation in specifically designed trials.
Authors
Gillessen, S.
Bossi, A.
Davis, I. D.
de Bono, J.
Fizazi, K.
James, N. D.
Mottet, N.
Shore, N.
Small, E.
Smith, M.
Sweeney, C. J.
Tombal, B.
Antonarakis, E. S.
Aparicio, A. M.
Armstrong, A. J.
Attard, G.
Beer, T. M.
Beltran, H.
Bjartell, A.
Blanchard, P.
Briganti, A.
Bristow, Robert G
Bulbul, M.
Caffo, O.
Castellano, D.
Castro, E.
Cheng, H. H.
Chi, K. N.
Chowdhury, S.
Clarke, C. S.
Clarke, Noel W
Daugaard, G.
De Santis, M.
Duran, I.
Eeles, R.
Efstathiou, E.
Efstathiou, J.
Ekeke, O. N.
Evans, C. P.
Fanti, S.
Feng, F. Y.
Fonteyne, V.
Fossati, N.
Frydenberg, M.
George, D.
Gleave, M.
Gravis, G.
Halabi, S.
Heinrich, D.
Herrmann, K.
Higano, C.
Hofman, M. S.
Horvath, L. G.
Hussain, M.
Jereczek-Fossa, B. A.
Jones, R.
Kanesvaran, R.
Kellokumpu-Lehtinen, P. L.
Khauli, R. B.
Klotz, L.
Kramer, G.
Leibowitz, R.
Logothetis, C.
Mahal, B.
Maluf, F.
Mateo, J.
Matheson, D.
Mehra, N.
Merseburger, A.
Morgans, A. K.
Morris, M. J.
Mrabti, H.
Mukherji, D.
Murphy, D. G.
Murthy, V.
Nguyen, P. L.
Oh, W. K.
Ost, P.
O'Sullivan, J. M.
Padhani, A. R.
Pezaro, C. J.
Poon, D. M. C.
Pritchard, C. C.
Rabah, D. M.
Rathkopf, D.
Reiter, R. E.
Rubin, M. A.
Ryan, C. J.
Saad, F.
Sade, J. P.
Sartor, O.
Scher, H. I.
Sharifi, N.
Skoneczna, I.
Soule, H.
Spratt, D. E.
Srinivas, S.
Sternberg, C. N.
Steuber, T.
Suzuki, H.
Sydes, M. R.
Taplin, M. E.
Tilki, D.
Türkeri, L.
Turco, F.
Uemura, H.
Uemura, H.
Ürün, Y.
Vale, C. L.
van Oort, I.
Vapiwala, N.
Walz, J.
Yamoah, K.
Ye, D.
Yu, E. Y.
Zapatero, A.
Zilli, T.
Omlin, A.
Bossi, A.
Davis, I. D.
de Bono, J.
Fizazi, K.
James, N. D.
Mottet, N.
Shore, N.
Small, E.
Smith, M.
Sweeney, C. J.
Tombal, B.
Antonarakis, E. S.
Aparicio, A. M.
Armstrong, A. J.
Attard, G.
Beer, T. M.
Beltran, H.
Bjartell, A.
Blanchard, P.
Briganti, A.
Bristow, Robert G
Bulbul, M.
Caffo, O.
Castellano, D.
Castro, E.
Cheng, H. H.
Chi, K. N.
Chowdhury, S.
Clarke, C. S.
Clarke, Noel W
Daugaard, G.
De Santis, M.
Duran, I.
Eeles, R.
Efstathiou, E.
Efstathiou, J.
Ekeke, O. N.
Evans, C. P.
Fanti, S.
Feng, F. Y.
Fonteyne, V.
Fossati, N.
Frydenberg, M.
George, D.
Gleave, M.
Gravis, G.
Halabi, S.
Heinrich, D.
Herrmann, K.
Higano, C.
Hofman, M. S.
Horvath, L. G.
Hussain, M.
Jereczek-Fossa, B. A.
Jones, R.
Kanesvaran, R.
Kellokumpu-Lehtinen, P. L.
Khauli, R. B.
Klotz, L.
Kramer, G.
Leibowitz, R.
Logothetis, C.
Mahal, B.
Maluf, F.
Mateo, J.
Matheson, D.
Mehra, N.
Merseburger, A.
Morgans, A. K.
Morris, M. J.
Mrabti, H.
Mukherji, D.
Murphy, D. G.
Murthy, V.
Nguyen, P. L.
Oh, W. K.
Ost, P.
O'Sullivan, J. M.
Padhani, A. R.
Pezaro, C. J.
Poon, D. M. C.
Pritchard, C. C.
Rabah, D. M.
Rathkopf, D.
Reiter, R. E.
Rubin, M. A.
Ryan, C. J.
Saad, F.
Sade, J. P.
Sartor, O.
Scher, H. I.
Sharifi, N.
Skoneczna, I.
Soule, H.
Spratt, D. E.
Srinivas, S.
Sternberg, C. N.
Steuber, T.
Suzuki, H.
Sydes, M. R.
Taplin, M. E.
Tilki, D.
Türkeri, L.
Turco, F.
Uemura, H.
Uemura, H.
Ürün, Y.
Vale, C. L.
van Oort, I.
Vapiwala, N.
Walz, J.
Yamoah, K.
Ye, D.
Yu, E. Y.
Zapatero, A.
Zilli, T.
Omlin, A.
Description
Date
2023
Publisher
Collections
Files
Keywords
Type
Article
Citation
Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, et al. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European journal of cancer (Oxford, England : 1990). 2023 Mar 3;185:178-215. PubMed PMID: 37003085. Epub 2023/04/02. eng.